Immunology for
a Better Future
Learn More
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Advancing Therapeutic
Solutions
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
Focused on Improving
Lives
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Key Highlights
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
OCALA, Fla., April 15, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM...
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful...